857283-89-7

Basic information

• Product Name: 3-PYRROLIDIN-1-YLBENZALDEHYDE
• Synonyms: 3-PYRROLIDIN-1-YLBENZALDEHYDE;3-(1-Pyrrolidinyl)Benzaldehyde
• CAS NO: 857283-89-7
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.23
• Product Categories: Carbonyl Compounds;Heterocycles
• Mol File: 857283-89-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 322.0℃
• Flash Point: 129.7℃
• Appearance: /
• Density: 1.125
• Vapor Pressure: 0.000287mmHg at 25°C
• Refractive Index: 1.599
• PKA: 5.68±0.20(Predicted)
• CAS DataBase Reference: 3-PYRROLIDIN-1-YLBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRROLIDIN-1-YLBENZALDEHYDE(857283-89-7)
• EPA Substance Registry System: 3-PYRROLIDIN-1-YLBENZALDEHYDE(857283-89-7)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 857283-89-7(Hazardous Substances Data)

Usage

Uses

3-(1-Pyrrolidinyl)benzaldehyde is used as a reactant in the preparation of rhodanine derivatives as protease inhibitors against bacterial toxins.

InChI:InChI=1/C11H13NO/c13-9-10-4-3-5-11(8-10)12-6-1-2-7-12/h3-5,8-9H,1-2,6-7H2

Upstream product

• 1141669-90-0 1-(3-(1,3-dioxolan-2-yl)phenyl)pyrrolidine 
• 17789-14-9 3-(1,3-dioxolan-2-yl)-phenylbromide 
• 3132-99-8 m-bromobenzoic aldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 219928-13-9 1-(3-bromophenyl)-pyrrolidine 

Downstream Products

• 1207549-76-5 C₂₂H₂₆BrN₃O₄ 

Relevant articles and documents

INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY

The invention provides amides that inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.